drugset / Trial / NCT00133796

Neoadjuvant Herceptin in Patients With Breast Cancer

NCT00133796 ↗

Phase 2 Terminated 40 enrolled Mothaffar Rimawi Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purposes of this study are to better understand how Herceptin causes tumors to become smaller and to find out how effective Herceptin, together with chemotherapy, is in treating advanced breast cancer.

Timeline

Start
2001-10
Primary completion
2005-09
Completion
2007-04

Outcome

Outcome not reported

Stopped (Enrollment): “Closed to accrual 4/19/2006 / Study doesn't qualify for reporting.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Trastuzumab Monoclonal antibody — —